Novel Agents Under Investigation for the Treatment of GIST
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses novel agents that are currently under investigation for the treatment of gastrointestinal stromal tumors
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses novel agents that are currently under investigation for the treatment of gastrointestinal stromal tumors (GIST).
Clinical Pearls
- Masitinib, a TKI, is currently in two ongoing phase III studies: one comparing it to imatinib in first-line treatment, and one comparing it to sunitinib in second-line treatment
- Mastinib targets the specific mutations in exon 11 at codon 557/558 that are relatively imatinib resistance as well as some of the wild type, non-KIT mutated, non-PDGFR mutated GIST
- Other drugs are looking at bypassing the KIT pathway completely, testing to see if other tyrosine-kinase pathways can be inhibited to get around the resistance
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
